Amyndas Biotherapeutics LLC is categorized under Commercial Biotechnical Research in Philadelphia, PA and active since 2012.
Amyndas Biotherapeutics LLC was established in 2012, and today employs 1 to 4, earning $50.000 to $99.999 per year. This is a Commercial Biotechnical Research business, which does work in the B2B market, and is classified as a Commercial Biotechnical Research, under code number 541711 by the NAICS.
If you are seeking more information, feel free to contact John Lambris at the company’s single location by writing to 3160 Chestnut St # 200, Philadelphia, Pennsylvania PA 19104 or by phoning (484) 620-3236. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Amyndas Biotherapeutics LLC |
| Contact Person: | John Lambris |
| Address: | 3160 Chestnut St # 200, Philadelphia, Pennsylvania 19104 |
| Phone Number: | (484) 620-3236 |
| Annual Revenue (USD): | $50.000 to $99.999 |
| Founded: | 2012 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Commercial Biotechnical Research |
| SIC Code: | 8731 |
| NAICS Code: | 541711 |
| Share This Business: |
Amyndas Biotherapeutics LLC was started in 2012 to provide professional Commercial Biotechnical Research under the SIC code 8731 and NAICS code 541711. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $50.000 to $99.999 per annum.
Feel free to contact John Lambris for inquiries that concern Amyndas Biotherapeutics LLC by calling the company number (484) 620-3236, as your correspondence is most welcome. Additionally, the physical location of the single location of Amyndas Biotherapeutics LLC can be found at the coordinates 39.953553,-75.18659 as well as the street address 3160 Chestnut St # 200 in Philadelphia, Pennsylvania 19104.
For its online presence, you may visit Amyndas Biotherapeutics LLC’s website at and engage with its social media outlets through on Twitter and on Facebook.